Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

Oligodeoxynucleotides (ODN) with unmethylated deoxycytidyl‐deoxyguanosine (CpG) dinucleotides (CpG ODN) mimic the immunostimulatory activity of bacterial DNA and are recognized by the Toll‐like receptor 9 (TLR9). CpG ODN of the B‐Class stimulate strong B cell and NK cell activation and cytokine production. The highest degrees of NK stimulation as well as IFN‐α secretion by plasmacytoid DC were found to occur only with A‐Class ODN. A third class of CpG ODN combines the immune effects of A‐ and B‐Class CpG ODN. C‐Class ODN strongly stimulate B cell or NK cell activation and IFN‐α production. In contrast to the A‐Class, the C‐Class is wholly phosphorothioate, has no poly‐G stretches, but has palindromic sequences combined with stimulatory CpG motifs. All classes stimulate TLR9‐dependent signaling, but with strikingly different dose‐response relationships that are quite in contrast to those observed for IFN‐α. Effects similar to those on human cells were observed on mouse splenocytes. In contrast, splenocytes from TLR9‐deficient mice did not show any response to the three CpG ODN classes. In vivo studies demonstrate that C‐Class ODN are very potent Th1adjuvants. C‐Class ODN may represent new therapeutic drugs that combine the effects of A‐ and B‐Class ODN for broad applications in infectious disease or cancer therapy.

[1]  R. Coffman,et al.  Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions , 2003, Journal of leukocyte biology.

[2]  S. Akira,et al.  The Roles of Toll-Like Receptor 9, MyD88, and DNA-Dependent Protein Kinase Catalytic Subunit in the Effects of Two Distinct CpG DNAs on Dendritic Cell Subsets1 , 2003, The Journal of Immunology.

[3]  E. Uhlmann,et al.  Recent advances in the development of immunostimulatory oligonucleotides. , 2003, Current opinion in drug discovery & development.

[4]  S. Akira,et al.  Cutting Edge: A Novel Toll/IL-1 Receptor Domain-Containing Adapter That Preferentially Activates the IFN-β Promoter in the Toll-Like Receptor Signaling1 , 2002, The Journal of Immunology.

[5]  R. Flavell,et al.  The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors , 2002, Nature.

[6]  Charles A. Janeway,et al.  IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling , 2002, Cell.

[7]  K. Ishii,et al.  CpG DNA: recognition by and activation of monocytes. , 2002, Microbes and infection.

[8]  R. Vabulas,et al.  Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments , 2002, European journal of immunology.

[9]  H. Wagner,et al.  Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 , 2002, Nature Immunology.

[10]  A. Krieg,et al.  Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. , 2002, Antisense & nucleic acid drug development.

[11]  K. Ishii,et al.  Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide , 2002, Journal of leukocyte biology.

[12]  T. Giese,et al.  Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1 , 2002, The Journal of Immunology.

[13]  R. Seder,et al.  CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates1 , 2002, The Journal of Immunology.

[14]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[15]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[16]  K. Ishii,et al.  Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells1 , 2001, The Journal of Immunology.

[17]  B. Blazar,et al.  Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. , 2001, Blood.

[18]  S. Akira,et al.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Hornung,et al.  Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells , 2001 .

[20]  K. Heeg,et al.  Suppressors of Cytokine Signaling (SOCS)-1 and SOCS-3 Are Induced by CpG-DNA and Modulate Cytokine Responses in APCs1 , 2001, The Journal of Immunology.

[21]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[22]  S. Akira,et al.  Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88 , 2000, Current Biology.

[23]  S. Akira,et al.  Immune Cell Activation by Bacterial Cpg-DNA through Myeloid Differentiation Marker 88 and Tumor Necrosis Factor Receptor–Associated Factor (Traf)6 , 2000, The Journal of experimental medicine.

[24]  R. Purcell,et al.  Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[25]  Gunther Hartmann,et al.  Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 , 2000, The Journal of Immunology.

[26]  A. Ullrich,et al.  Cell type‐specific activation of mitogen‐activated protein kinases by CpG‐DNA controls interleukin‐12 release from antigen‐presenting cells , 1999, The EMBO journal.

[27]  Fyaz M. D. Ismail,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  L. Manzel,et al.  Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide. , 1999, Antisense & nucleic acid drug development.

[29]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[30]  A. Krieg,et al.  Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. , 1998, Journal of immunology.

[31]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[32]  A. Krieg,et al.  Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. , 1996, Journal of immunology.

[33]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[34]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.

[35]  K. Ishii,et al.  Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs , 2001 .

[36]  V. Hornung,et al.  Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. , 2001, European journal of immunology.

[37]  H. Davis Use of CpG DNA for enhancing specific immune responses. , 2000, Current topics in microbiology and immunology.